First, the exclusion of participants without documented baseline CD4 counts or WHO staging may have introduced selection bias, if those who were excluded were more likely to present with AHD or experience one of the study outcomes we investigated. The gene discussed is CD4; the disease is mitochondrial DNA depletion syndrome 4a.